C. difficile is a very common bacterium (a germ that may cause disease) that can live in the human gut. Some people have it without having any symptoms, but in others it can cause illness ranging from mild diarrhea to severe colitis (infection of the colon). In some cases, C. difficile infection results in death.
Sanofi Pasteur is developing a vaccine which directs the immune system to produce antibodies against C.diff toxins. C.diff is emerging as a leading cause of life threatening, health-care acquired infections worldwide. 350,000 Americans are hospitalized every year due to C.diff – 77% of cases are people over 50 years old.
C.diff symptoms range from mild diarrhea to life –threatening colitis and often include dehydration, abdominal pain and spasms.
For more information about this study visit http://www.cdiffense.org/home.
You may qualify for this study if you are 50 years of age or older and meet requirements of group 1 or 2 listed below:
- Have had at least 2 hospital stays, each lasting at least 24 hours or more in the past 12 months
- Have received systemic (not topical) antibiotics in the past 12 months
- Are you anticipating an in-patient hospitalization for a planned surgical procedure within the next 60 days?
- Is the upcoming hospital stay planned to be ≥ 72 hours for a surgery involving 1 of the following?
- Kidney/bladder/urinary system
- Musculoskeletal system
- Respiratory system
- Circulatory system
- Central nervous system
Click HERE for more information on this trial from clinicaltrials.gov.